Peter Grimm

About

Peter Grimm is a leading figure in prostate cancer research, with his work fundamentally shaping how clinicians evaluate and compare treatment outcomes. His primary research areas center on the comparative effectiveness of radical therapies for prostate cancer, with a particular focus on brachytherapy as a state-of-the-art radiotherapy option. Grimm’s most impactful contribution is his landmark 2012 study, "Comparative analysis of prostate‐specific antigen free survival outcomes," which has garnered 459 citations. This work provided a critical, systematic comparison of treatment results—from surgery to radiation—using PSA as the most sensitive measure of effectiveness, filling a major gap in the literature where few such comparative studies existed. By synthesizing data across low, intermediate, and high-risk patient groups, Grimm offered clinicians and patients a clearer, evidence-based framework for decision-making. His 2015 paper on brachytherapy further underscores his influence, highlighting how treatment-related toxicities, quality of life, and convenience are as vital as efficacy in modern prostate cancer care. Through these contributions, Grimm has not only advanced the science of comparative effectiveness but also championed a more patient-centered approach to oncology.

Research Focus

Key Achievements

Top Papers

1. 1
   Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group

   459 citations · 2012
2. 2
   Brachytherapy: state‐of‐the‐art radiotherapy in prostate cancer

   28 citations · 2015
3. 3
   Low and Intermediate Risk Prostate Cancer - Comparative Effectiveness of Brachytherapy, Cryotherapy, External Beam Radio Therapy, HIFU, Proton Therapy, Radical Prostatectomy, and Robot Assisted Radical Prostatectomy

   2 citations · 2009

Key Collaborators

Contact & Links